PROS1 and COVID-19: Based on our findings, which demonstrated higher frequencies of N- and M-reactive T-cell responses at disease onset, we hypothesize that our VBI diseased cohort presents with decreased immunity against SARS-CoV-2 WT and alpha S protein after the prime-boost COVID-19 vaccination.